Clinical and immunological features of 177 patients with primary Sjögren’s syndrome
| Values are n (%) or mean (SD). | ||
| *Bronchial involvement (n = 7), bronchiolar involvement (n = 6), interstitial disease (n = 6), alveolar disease (n = 1). | ||
| †Patients with lymphoma were excluded from serum β2 microglobulin analysis. | ||
| CNS, central nervous system; ESR, erythrocyte sedimentation rate. | ||
| Enlarged parotid glands | 52 (29.4%) | |
| Raynaud’s phenomenon | 61 (34.5%) | |
| Extraglandular involvement | 73 (41.2%) | |
| Purpura | 13 (7.3%) | |
| Synovitis | 29 (16.4%) | |
| Myositis | 5 (2.8%) | |
| Lung involvement* | 20 (11.3%) | |
| CNS involvement/peripheral neuropathy | 2 (1.1%)/16 (9%) | |
| Lymphoma† | 6 (3.4%) | |
| Medium sized vessel vasculitis/lymphadenopathy/enlarged spleen | 1 (0.5%)/4 (2.2%)/1 (0.5%) | |
| Serum β2 microglobulin (mg/l) (n = 154) | 1.9 (0.9) | |
| Serum BLyS (ng/ml) (n = 137) | 5.5 (7.3) | |
| Lymphopenia | 68 (38.4%) | |
| Positive rheumatoid factor results | 92 (51.9%) | |
| Rheumatoid factor (IU/ml) | 159.1 (344.8) | |
| Serum gamma globulin (g/l) | 13.3 (6.7) | |
| Serum IgG (g/l) | 15 (6.9) | |
| Serum IgA (g/l) | 3.0 (1.5) | |
| Serum IgM (g/l) | 1.6 (1.3) | |
| Serum C3 (g/l) (n = 146) | 1.0 (0.3) | |
| Serum C4 (g/l) (n = 146) | 0.2 (0.1) | |
| ESR (mm/h) | 27.8 (23.4) | |
| C reactive protein (mg/l) (n = 114) | 8.4 (10.0) | |
| No anti-SSA or anti-SSB antibodies | 66 (37.3%) | |
| Anti-SSA antibody only | 53 (29.9%) | |
| Anti-SSA and anti-SSB antibodies | 58 (32.8%) | |
| Focus score ⩾1 on labial salivary gland (n = 168) | 153 (91.1%) | |